Aluminum Hydroxide
CAS 21645-51-2
Aluminum Hydroxide (CAS 21645-51-2) is a Phase 4 pharmaceutical compound with 0 bioactivity targets and 888 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Schizoaffective disorder | 103 | 474.937 | 10039621 |
| Drug level increased | 105 | 255.494 | 10013722 |
| Electrocardiogram QT prolonged | 113 | 195.674 | 10014387 |
| Drug interaction | 156 | 110.345 | 10013710 |
| Mesothelioma | 10 | 44.106 | 10027406 |
| Drug ineffective | 35 | 42.691 | 10013709 |
| Acute myocardial infarction | 38 | 35.761 | 10000891 |
| Sinus rhythm | 10 | 35.751 | 10048815 |
| Hyponatraemia | 56 | 32.533 | 10021036 |
| Violence-related symptom | 8 | 29.002 | 10047426 |
| Hepatic cytolysis | 21 | 28.063 | 10049199 |
| Delirium | 35 | 26.78 | 10012218 |
| Appendicolith | 13 | 26.201 | 10074458 |
| Blood phosphorus increased | 14 | 25.911 | 10050196 |
| Vomiting | 127 | 25.219 | 10047700 |
| Hypercapnia | 13 | 24.745 | 10020591 |
| General physical health deterioration | 67 | 23.481 | 10049438 |
| Morbid thoughts | 6 | 20.645 | 10050464 |
| Exposure during pregnancy | 44 | 20.606 | 10073513 |
| IVth nerve paresis | 3 | 20.134 | 10054201 |
| Analgesic therapy | 6 | 19.646 | 10053469 |
| Sleep disorder therapy | 6 | 19.524 | 10040990 |
| Maternal drugs affecting foetus | 12 | 19.509 | 10026923 |
| Fatigue | 45 | 18.814 | 10016256 |
| Ventricular fibrillation | 18 | 18.809 | 10047290 |
| Erysipelas | 12 | 18.754 | 10015145 |
| Drug therapy | 6 | 18.568 | 10063370 |
| Appendicitis | 15 | 18.365 | 10003011 |
| Diabetic foot | 8 | 17.793 | 10060734 |
| Anal incontinence | 14 | 17.4 | 10077605 |
| Acute kidney injury | 89 | 17.128 | 10069339 |
| Seizure | 49 | 16.971 | 10039906 |
| Coma scale abnormal | 10 | 16.792 | 10069709 |
| Blood uric acid increased | 12 | 16.749 | 10005861 |
| Caesarean section | 13 | 16.537 | 10006924 |
| Cardio-respiratory arrest | 31 | 16.526 | 10007617 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| ALUMINUM HYDROXIDE | 612 | SU | MTHSPL |
| Aluminum Hydroxide | 612 | SU | MTHSPL |
| aluminum hydroxide | 612 | SU | MTHSPL |
| aluminum hydroxide | 612 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Aluminum Hydroxide used for in pharmaceutical contexts?
Aluminum Hydroxide (CAS 21645-51-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Aluminum Hydroxide?
Aluminum Hydroxide has 888 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Schizoaffective disorder, Drug level increased, Electrocardiogram QT prolonged, Drug interaction, Mesothelioma. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Aluminum Hydroxide also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Aluminum Hydroxide with EU status "permitted".
What clinical phase is Aluminum Hydroxide in?
Aluminum Hydroxide is rendered with ChEMBL max phase 4 (approved).